The objective of this trial is to assess the safety and feasibility of delivering SBRT to patients with limited BMs (less than 10 lesions of lung cancer) by establishing the maximally tolerated dose (MTD) of SABR in 5 fractions.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histology confirmed that it was non-small cell lung cancer
1 to 10 brain metastases detected by magnetic resonance imaging (MRI)
A life expectancy of \>3 months according to the DS GPA.
KPS ≥70
Control of the primary lesions (thorax) at the time of SBRT
2cm\<Tumor size ≤ 4 cm
Age of 18-75 years old
Patients must be able to undergo contrast enhanced MRI for planning
Adequate bone marrow and organ function
You may not be if
other malignant tumors
Prior surgery to brain metastasis
Prior brain radiotherapy
Non-small cell lung cancer with more than 10 brain metastases detected by MRI
Contraindication to receiving radiotherapy.
Clareo Health | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer
